FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083924947> ?p ?o ?g. }

• W2083924947 abstract "To determine the relative cost-effectiveness of three classes of antidepressants: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and the modified TCA lofepramine, as first choice treatments for depression in primary care.Open, pragmatic, controlled trial with three randomised arms and one preference arm. Patients were followed up for 12 months.UK primary care: 73 practices in urban and rural areas in England.Patients with a new episode of depressive illness according to GP diagnosis.Patients were randomised to receive a TCA (amitriptyline, dothiepin or imipramine), an SSRI (fluoxetine, sertraline or paroxetine) or lofepramine. Patients or GPs were able to choose an alternative treatment if preferred.At baseline the Clinical Interview Schedule, Revised (CIS-R PROQSY computerised version) was administered to establish symptom profiles. Outcome measures over the 12-month follow-up included the Hospital Anxiety and Depression Scale self-rating of depression (HAD-D), CIS-R, EuroQol (EQ-5D) for quality of life, Short Form (SF-36) for generic health status, and patient and practice records of use of health and social services. The primary effectiveness outcome was the number of depression-free weeks (HAD-D less than 8, with interpolation of intervening values) and the primary cost outcome total direct NHS costs. Quality-adjusted life-years (QALYs) were used as the outcome measure in a secondary analysis. Incremental cost-effectiveness ratios and cost-effectiveness acceptability curves were computed. Estimates were bootstrapped with 5000 replications.In total, 327 patients were randomised. Follow-up rates were 68% at 3 months and 52% at 1 year. Linear regression analysis revealed no significant differences between groups in number of depression-free weeks when adjusted for baseline HAD-D. A higher proportion of patients randomised to TCAs entered the preference arm than those allocated to the other choices. Switching to another class of antidepressant in the first few weeks of treatment occurred significantly more often in the lofepramine arm and less in the preference arm. There were no significant differences between arms in mean cost per depression-free week. For values placed on an additional QALY of over 5000 pounds, treatment with SSRIs was likely to be the most cost-effective strategy. TCAs were the least likely to be cost-effective as first choice of antidepressant for most values of a depression-free week or QALY respectively, but these differences were relatively modest.When comparing the different treatment options, no significant differences were found in outcomes or costs within the sample, but when outcomes and costs were analysed together, the resulting cost-effectiveness acceptability curves suggested that SSRIs were likely to be the most cost-effective option, although the probability of this did not rise above 0.6. Choosing lofepramine is likely to lead to a greater proportion of patients switching treatment in the first few weeks. Further research is still needed on the management of depressive illness in primary care. This should address areas such as the optimum severity threshold at which medication should be used; the feasibility and effectiveness of adopting structured depression management programmes in the UK context; the importance of factors such as physical co-morbidity and recent life events in GPs' prescribing decisions; alternative ways of collecting data; and the factors that give rise to many patients being reluctant to accept medication and discontinue treatment early." @default.
• W2083924947 created "2016-06-24" @default.
• W2083924947 creator A5001719412 @default.
• W2083924947 creator A5003030076 @default.
• W2083924947 creator A5005328949 @default.
• W2083924947 creator A5011917236 @default.
• W2083924947 creator A5033267681 @default.
• W2083924947 creator A5046647690 @default.
• W2083924947 creator A5053346837 @default.
• W2083924947 creator A5061722920 @default.
• W2083924947 creator A5065647766 @default.
• W2083924947 creator A5067471315 @default.
• W2083924947 creator A5075987958 @default.
• W2083924947 creator A5085530355 @default.
• W2083924947 date "2005-05-01" @default.
• W2083924947 modified "2023-10-11" @default.
• W2083924947 title "A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine" @default.
• W2083924947 doi "https://doi.org/10.3310/hta9160" @default.
• W2083924947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15876362" @default.
• W2083924947 hasPublicationYear "2005" @default.
• W2083924947 type Work @default.
• W2083924947 sameAs 2083924947 @default.
• W2083924947 citedByCount "72" @default.
• W2083924947 countsByYear W20839249472012 @default.
• W2083924947 countsByYear W20839249472013 @default.
• W2083924947 countsByYear W20839249472014 @default.
• W2083924947 countsByYear W20839249472015 @default.
• W2083924947 countsByYear W20839249472016 @default.
• W2083924947 countsByYear W20839249472017 @default.
• W2083924947 countsByYear W20839249472019 @default.
• W2083924947 countsByYear W20839249472021 @default.
• W2083924947 countsByYear W20839249472022 @default.
• W2083924947 countsByYear W20839249472023 @default.
• W2083924947 crossrefType "journal-article" @default.
• W2083924947 hasAuthorship W2083924947A5001719412 @default.
• W2083924947 hasAuthorship W2083924947A5003030076 @default.
• W2083924947 hasAuthorship W2083924947A5005328949 @default.
• W2083924947 hasAuthorship W2083924947A5011917236 @default.
• W2083924947 hasAuthorship W2083924947A5033267681 @default.
• W2083924947 hasAuthorship W2083924947A5046647690 @default.
• W2083924947 hasAuthorship W2083924947A5053346837 @default.
• W2083924947 hasAuthorship W2083924947A5061722920 @default.
• W2083924947 hasAuthorship W2083924947A5065647766 @default.
• W2083924947 hasAuthorship W2083924947A5067471315 @default.
• W2083924947 hasAuthorship W2083924947A5075987958 @default.
• W2083924947 hasAuthorship W2083924947A5085530355 @default.
• W2083924947 hasBestOaLocation W20839249471 @default.
• W2083924947 hasConcept C112930515 @default.
• W2083924947 hasConcept C118552586 @default.
• W2083924947 hasConcept C126322002 @default.
• W2083924947 hasConcept C139719470 @default.
• W2083924947 hasConcept C159110408 @default.
• W2083924947 hasConcept C162324750 @default.
• W2083924947 hasConcept C168563851 @default.
• W2083924947 hasConcept C170493617 @default.
• W2083924947 hasConcept C2775864247 @default.
• W2083924947 hasConcept C2776134451 @default.
• W2083924947 hasConcept C2776867660 @default.
• W2083924947 hasConcept C2777286182 @default.
• W2083924947 hasConcept C2777669559 @default.
• W2083924947 hasConcept C2779177272 @default.
• W2083924947 hasConcept C2779951463 @default.
• W2083924947 hasConcept C2984752397 @default.
• W2083924947 hasConcept C3019080777 @default.
• W2083924947 hasConcept C512399662 @default.
• W2083924947 hasConcept C558461103 @default.
• W2083924947 hasConcept C64332521 @default.
• W2083924947 hasConcept C71924100 @default.
• W2083924947 hasConceptScore W2083924947C112930515 @default.
• W2083924947 hasConceptScore W2083924947C118552586 @default.
• W2083924947 hasConceptScore W2083924947C126322002 @default.
• W2083924947 hasConceptScore W2083924947C139719470 @default.
• W2083924947 hasConceptScore W2083924947C159110408 @default.
• W2083924947 hasConceptScore W2083924947C162324750 @default.
• W2083924947 hasConceptScore W2083924947C168563851 @default.
• W2083924947 hasConceptScore W2083924947C170493617 @default.
• W2083924947 hasConceptScore W2083924947C2775864247 @default.
• W2083924947 hasConceptScore W2083924947C2776134451 @default.
• W2083924947 hasConceptScore W2083924947C2776867660 @default.
• W2083924947 hasConceptScore W2083924947C2777286182 @default.
• W2083924947 hasConceptScore W2083924947C2777669559 @default.
• W2083924947 hasConceptScore W2083924947C2779177272 @default.
• W2083924947 hasConceptScore W2083924947C2779951463 @default.
• W2083924947 hasConceptScore W2083924947C2984752397 @default.
• W2083924947 hasConceptScore W2083924947C3019080777 @default.
• W2083924947 hasConceptScore W2083924947C512399662 @default.
• W2083924947 hasConceptScore W2083924947C558461103 @default.
• W2083924947 hasConceptScore W2083924947C64332521 @default.
• W2083924947 hasConceptScore W2083924947C71924100 @default.
• W2083924947 hasFunder F4320334661 @default.
• W2083924947 hasIssue "16" @default.
• W2083924947 hasLocation W20839249471 @default.
• W2083924947 hasLocation W20839249472 @default.
• W2083924947 hasOpenAccess W2083924947 @default.
• W2083924947 hasPrimaryLocation W20839249471 @default.
• W2083924947 hasRelatedWork W1587575409 @default.
• W2083924947 hasRelatedWork W2048787387 @default.
• W2083924947 hasRelatedWork W2078288176 @default.
• W2083924947 hasRelatedWork W2083924947 @default.
• W2083924947 hasRelatedWork W2363007441 @default.

• next